J&J bags $150M option on Genmab's Darzalex successor

Genmab and Johnson & Johnson have teamed up to develop a successor to their multiple myeloma blockbuster Darzalex. The deal gives J&J the option to license the asset after clinical proof of concept for $150 million (€132 million) plus milestones and royalties.